Jim Cramer Says to Buy UnitedHealth Group Stock. Is He Right?

UnitedHealth stock has surged about 57% since March 30 to $408 per share after CMS proposed a 2.48% rate increase for Medicare Advantage insurers in 2027. The article argues the stock still looks inexpensive at 21x forward earnings, with 77% of analysts rating it a buy and a median price target of $420, supported by last quarter's earnings beat and raised 2026 guidance. The piece also highlights Cramer's bullish view and UnitedHealth's defensive dividend profile.

Analysis

The market is treating UNH like a quality-duration asset again, but the more important shift is that policy clarity is compressing its equity risk premium faster than fundamentals are improving. That creates a mechanical bid from defensive allocators, quant trend followers, and income mandates that were underweight after the drawdown; in other words, the stock can keep rising even if operating results merely normalize rather than inflect sharply. The risk is that the next leg higher becomes harder unless earnings revisions broaden beyond a re-rating story.

Second-order, UNH’s move is a read-through on managed care dispersion: scale players with better rate negotiation and administrative leverage should outperform smaller MA-exposed names, while any carrier with weaker medical cost discipline gets squeezed by the same policy headline. HUM likely benefits on sympathy, but the market should still pay up more for earnings quality than for simple beta to CMS rates. If this becomes a “safety stock” trade, it can crowd quickly and then unwind on any sign that utilization or pricing discipline is weaker than investors assume.

The consensus may be underestimating two timing risks: first, CMS-driven optimism is a 2027 earnings issue, while near-term price action is already discounting a cleaner 12–18 month path; second, a strong move in a defensive can invite profit-taking from event-driven holders once valuation moves from obviously cheap to merely reasonable. The best contrarian setup is not to short UNH outright, but to fade the crowding via relative value against lower-quality managed care exposure or through call spreads that monetize upside while capping chase risk.

Key Decisions for Investors

• Stay long UNH but reduce chase risk with a 3-6 month call spread rather than outright equity; use pullbacks toward the 20-day moving average as entry, since the trade is now mostly multiple expansion rather than pure fundamental rerating.
• Pair trade: long UNH / short HUM for 1-2 quarters. Thesis: scale, mix, and balance-sheet quality should let UNH keep compounding while HUM remains more exposed to any disappointment in medical cost trends and Medicare Advantage execution.
• For defensive equity exposure, rotate into UNH on weakness and fund it by trimming lower-quality healthcare names; expected payoff is lower drawdown sensitivity in a risk-off tape, with better earnings visibility over the next 2-3 quarters.
• Avoid initiating a fresh short in UNH here; if you want to express contrarian views, do it via downside hedges or relative shorts because the momentum/defensive flow support can persist for weeks longer than valuation skeptics expect.